PLG
Plasminogen [Cleaved into: Plasmin
As of the edition of 20 October 2026, PLG (plasminogen [Cleaved into: Plasmin, UniProt P00747) has 8 drugs tested at it and 15 companies on the list, 2 on route A and 5 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- P00747
- How well studied
- Drug target: an approved drug acts on it
- Where it sits in the cell
- Secreted
- Solved structures
- 49
- Disease areas
- Urinary and reproductive; Pregnancy and women's health; Injuries; Heart and blood vessels; Bones, joints and muscles; Cancer; Blood and lymph; Skin and connective tissue
- Registered trials of its drugs
- 520
Drugs at this target
| Status | Count |
|---|---|
| Marketed | 6 |
| Stopped | 1 |
| Status not established | 1 |
| Total | 8 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| Tranexamic acid | Marketed | Phase 4 | none listed |
| Defibrotide | Marketed | Phase 4 | none listed |
| Aminocaproic acid | Marketed | Phase 4 | none listed |
| Aprotinin | Marketed | Phase 4 | Ended 2005 |
| Streptokinase | Marketed | Phase 4 | none listed |
| Desmoteplase | Stopped | Phase 3 | none listed |
| BT-114143 | Status not established | Phase 1 | none listed |
| Defibrotide sodium | Marketed | No phase stated | none listed |
8 of 8 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Route A | 2 |
| Route B | 5 |
| Engaged | 3 |
| Undetermined | 5 |
| Total on the list | 15 |
| Company | Route |
|---|---|
| Pfizer | Route B |
| Adium | Route B |
| Nippon Shinyaku | Route B |
The other 12 companies at PLG
In the product15 companies in all; 12 are not named here, and no score is.
See the 15 companies at PLG, ranked, with the facts behind eachRequest access. Nothing is shown until you do.